Citations

Mayo Clinic

Clear

1932 citation(s) found for "Wu, Jessica".

Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Vorasoot, Nisa , Abdulrahman, Yahya, Mateen, Farrah J. , Fryer, James P., Redenbaugh, Vyanka , Sagen, Jessica, Jenkins, Sarah M. , Gorsh, Amy P., Chen, John J. , Ζεκερίδου, Αναστασία , Mills, John R. , Pittock, Sean J. , Pittock, S J , Abdulrahman, Yahya J, Mateen, Farrah , Sagen, Jessica A., Zekeridou, Anastasia , McKeon, Andrew , Flanagan, E P , Chen, John J , Vorasoot, Nisa , Musubire, Abdu Kisekka , McKeon, Andrew , Flanagan, Eoin P.

Annals of Clinical and Translational Neurology | October 15, 2024 | Volume: 11 | Issue: 11 | Pages: 2855-2865

10.1002/acn3.52178 | PMID 39406378 Get It

AbstractObjectiveThis study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing.MethodsProspective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared.ResultsAmong 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases.InterpretationThe DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing.
PEDIATRIC MACULAR HOLE ASSOCIATED WITH VITREORETINAL TRACTION ON EPIRETINAL LESIONS: A CASE REPORT AND LITERATURE REVIEW
Said, Reeda Bou , Kraker, Jessica A. , Trejo‐Lopez, Jorge , Salomão, Diva R. , Scruggs, Brittni A. , Scruggs, Brittni A

RETINAL Cases & Brief Reports | October 14, 2024 | Volume: 19 | Issue: 6 | Pages: 730-735

10.1097/icb.0000000000001663 | PMID 39733272 Get It

Purpose: We describe a case of nontraumatic macular hole in a pediatric patient associated with numerous epiretinal lesions throughout the macula. Methods: A healthy 9-year-old girl presented to retina clinic with several months of blurry vision in the right eye. Clinically, there was a full-thickness macular hole with serous detachment and white epiretinal tufts. Spectral-domain optical coherence tomography confirmed the presence of the full-thickness macular hole with hyperreflective epiretinal proliferations in the right eye and an unremarkable left eye. Systemic workup was negative. After a short period of observation, the patient underwent vitrectomy with internal limiting membrane peel and 14% C3F8 gas tamponade in the right eye. Multiple intraoperative samples were sent for further testing, which were also negative. Results: At 1- and 12 months/1 year postoperative visits, examination showed successful closure of the full-thickness macular hole with resolution of the subretinal fluid and improved VA. Conclusion: Nontraumatic macular holes in pediatric patients warrant systemic and ocular workup, including fluorescein angiography and laboratory testing. Good anatomic and visual outcomes are generally seen with spontaneous and surgical closures of macular holes in this age group. Early vitrectomy with histologic analysis of ocular samples should be considered in pediatric macular hole cases associated with vitreoretinal traction, especially those with epiretinal abnormalities.
DICER1 -Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Schultz, Kris Ann P. , Nelson, Alexander T. , Mallinger, Paige, Harris, Anne K. , Kamihara, Junne , Baldinger, Shari , Chen, Kenneth , Pond, Dinel , Hatton, Jessica N. , Dybvik, Anna, Perrino, Melissa R. , Ami, Tal Ben , Su, Yan , Duan, Cuihai , Watson, David , Field, Amanda L., Carr, Ann G. , Schneider, Dominik T. , Schoettler, Peter , Dehner, Louis P. , Mallinger, Paige H R , Chen, Kenneth S , Dybvik, Anna G , Mitchell, Sarah G , Perrino, Melissa R , Ben-Ami, Tal , Kachanov, Denis , Su, Yan , Duan, Chao , Olson, Damon R , Watson, Dave , Field, Amanda L , Harney, Laura A , Garrity Carr, Ann , Frazier, A Lindsay , Schneider, Dominik T , Wilson, David B , MacFarland, Suzanne P , Schoettler, Peter J , Bauer, Andrew J , Dehner, Louis P , Hill, Dana Ashley , Stewart, Douglas R , Messinger, Yoav H , Harris, Anne K , Olson, Damon R. , Wilson, David B. , Messinger, Yoav H.

Clinical Cancer Research | October 14, 2024 | Volume: 30 | Issue: 24 | Pages: 5681-5692

10.1158/1078-0432.ccr-24-1532 | PMID 39400264 Get It

Abstract Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.
Prenatal Ultrasonographic Features Associated With ARSL and X‐Linked Chondrodysplasia Punctata 1 (CDPX1): Literature Review and Case Series
Broeren, Eleanor , Stover, Samantha, Bennett, Katya, Giordano, Jessica L. , Galloway, Stephanie, Lauzon, Julie, Rust, Laura, Suerink, Manon , Haeringen, Arie van , Team, Australian Genomic Autopsy Study, Reimers, Rebecca, Giordano, Jessica , Broeren, Eleanor C , Stover, Samantha R. , Team, Australian Genomic Autopsy Study, Reimers, Rebecca

Prenatal Diagnosis | October 8, 2024 | Volume: 44 | Issue: 13 | Pages: 1663-1670

10.1002/pd.6649 | PMID 39313411 Get It

ABSTRACT Background Chondrodysplasia punctata 1 (CDPX1) is an X‐linked recessive disorder of cartilage and bone development characterized by stippling on the cartilage and bone, flattened nasal bridge, and brachydactyly, or short fingers. CDPX1 has been associated with variants in the ARSL gene and is known to manifest prenatally, however, there has been no systematic literature review on this evidence. Aims Here, we reviewed the current literature on prenatal manifestations of CDPX1, and additionally introduce previously unpublished cases. Materials & Methods A systematic review of the literature was performed. Additionally, a GeneMatcher submission was created and a call for cases was presented at the Fetal Sequencing Consortium meetings to find previously unpublished cases. Results For the 22 fetuses reported here, we found that 55% had nasal hypoplasia, 41% had bony stippling or calcifications, 32% had polyhydramnios, 5% had oligohydramnios, 23% had shortened long bones, 23% had spinal canal stenosis, 18% had ventriculomegaly, 9% had brachydactyly/brachytelephalangy, 9% had clubbed feet, 9% had premature rupture of membranes, and 9% had intraventricular hemorrhage detected through sonography or radiography. We also found 17 unique variants in ARSL for these 22 fetuses. Discussion A previously unpublished association of ARSL variants with intrauterine fetal death or stillbirth has been noted in this study. It is also possible that intracranial hemorrhage is an underrecognized feature associated with CDPX1 variation. However, there have been challenges in applying ACMG criteria to ARSL, a gene without an associated Variant Curation Expert Panel. Conclusion This literature review and case series highlights which features of CDPX1 manifest prenatally, as well as introduces new phenotypes that have not been previously identified.
Defining standards for fluoroscopy in gastrointestinal endoscopy using Delphi methodology
Khalaf, Kareem , Pawlak, Katarzyna M. , Alkandari, Asma , Baron, Todd H. , Bechara, Robert , Binda, Cecilia , Chen, Yen‐I , Moura, Eduardo Guimarães Hourneaux de , Forbes, Nauzer , James, Paul, Martin, Harry , May, Gary R. , Mosko, Jeffrey D. , Oyeleke, Ganiyat K. , Petersen, Bret T. , Saxena, Payal , Sethi, Amrita , Sharaiha, Reem Z. , Tang, Raymond S. , Villarroel, Mariano , Hooft, Jeanin E. van , Renteln, Daniel von , Walsh, Catharine M. , Aberin, Tricia, Banavage, Dawn, Chen, Jowell Akina, Clancy, James, Drake, Heather, Im, Melanie, Low, Chooi Peng, Myszko, Alexandra, Navarro, Krista, Redman, Jessica, Reyes, Wayne, Weinstein, Faina, Na, Caleb, Tham, Daniel , He, Tony , Malipatil, Sharan B., Gimpaya, Nikko , Kundra, Arjun , Grover, Samir C. , Barkun, Alan N , Bechara, Robert , Binda, Cecilia , de Moura, Eduardo , Hassan, Cesare , Kahaleh, Michel , Sharaiha, Reem Z , Villarroel, Mariano , van Hooft, Jeanin E , Voermans, Rogier P , von Renteln, Daniel , Walsh, Catharine M , Gupta, Sunil , Fujiyoshi, Yusuke , Grover, Samir C , Causada Calo, Natalia S , Pawlak, Katarzyna M , Adler, Douglas G. , Barkun, Alan , Berzin, Tyler M. , Cai, Ming‐Yan , Carrara, Silvia , Fugazza, Alessandro , Hassan, Cesare , James, Paul D., Kahaleh, Michel , Maselli, Roberta , Repici, Alessandro , Spadaccini, Marco , Teshima, Christopher , Voermans, Rogier P. , Clancy, James, Reyes, Wayne, Gupta, Sunil , Mokhtar, Ahmed H., Gholami, Reza

Endoscopy International Open | October 7, 2024 | Volume: 12 | Issue: 11 | Pages: E1315-E1325

10.1055/a-2427-3893 | PMID 39559412 Get It

Abstract Background and study aims Use of fluoroscopy in gastrointestinal endoscopy is an essential aid in advanced endoscopic interventions. However, it also raises concerns about radiation exposure. This study aimed to develop consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, prioritizing the safety and well-being of healthcare workers and patients. Methods A modified Delphi approach was employed to achieve consensus over three rounds of surveys. Proposed statements were generated in Round 1. In the second round, panelists rated potential statements on a 5-point scale, with consensus defined as ≥80% agreement. Statements were subsequently prioritized in Round 3, using a 1 (lowest priority) to 10 (highest priority) scale. Results Forty-six experts participated, consisting of 34 therapeutic endoscopists and 12 endoscopy nurses from six continents, with an overall 45.6% female representation (n = 21). Forty-three item statements were generated in the first round. Of these, 31 statements achieved consensus after the second round. These statements were categorized into General Considerations (n = 6), Education (n = 10), Pregnancy (n = 4), Family Planning (n = 2), Patient Safety (n = 4), and Staff Safety (n = 5). In the third round, accepted statements received mean priority scores ranging from 7.28 to 9.36, with 87.2% of statements rated as very high priority (mean score ≥ 9). Conclusions This study presents consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, addressing the well-being of healthcare workers and patients. These consensus-based statements aim to mitigate risks associated with radiation exposure while maintaining benefits of fluoroscopy, ultimately promoting a culture of safety in healthcare settings.
7787 Primary Aldosteronism Medical Treatment Outcomes (PAMO): An International Consensus on Outcome Assessment Criteria and Multicentre Study
Goi, Jessica , Investigators, Parkinson Study Group CALM Cohort, Yang, Jun , Burrello, Jacopo , Williams, Tracy Ann , Young, William F. , Fuller, Peter J

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.604 Get It

Abstract Disclosure: J. Yang: None. J. Burrello: None. J. Goi: None. T.A. Williams: None. W.F. Young: Consulting Fee; Self; Arena Pharmaceuticals, Inc.. Other; Self; Crinetics Pharmaceuticals. P.J. Fuller: None. P. Investigators: None. Primary aldosteronism (PA) is the most common endocrine cause of hypertension. Mineralocorticoid receptor antagonists, at adequate doses, lower blood pressure and cardiovascular risk in patients with PA. However, there is a lack of a standardized approach to medical therapy and subsequent outcomes assessment. We aimed to: 1) establish criteria for assessing outcomes of targeted medical treatment of PA, and 2) evaluate outcomes using these criteria across an international cohort. A panel of 31 PA experts from 31 centres across four continents used the Delphi method, including three rounds of online questionnaires, to reach consensus. Clinical data were then collected from consecutive patients with PA who started targeted medical treatment between 2016 and 2021 at the participating centres. Consensus was reached for six outcomes, including complete, partial, or absent biochemical response, and complete, partial, or absent clinical response. “Complete biochemical response” was defined as “correction of hypokalemia without potassium supplementation, and normalization of plasma renin activity or concentration”; while “absent biochemical response” was defined as “persistent hypokalemia and/or persistently suppressed or low plasma renin activity or concentration without change from baseline”. “Complete clinical response” was defined as “normal blood pressure without additional antihypertensive medications”; while “absent clinical response” was defined as “the same or increased blood pressure compared to before targeted treatment with same or more antihypertensive medications, not counting targeted therapy”. Of 1483 patients (mean age 52y, 48% female) from 28 centers, 232 (16%) had a complete clinical response, and 719 (49%) had a complete biochemical response at the most recent follow-up (median 29 months after treatment initiation). Compared to those with partial or absent clinical response, patients with complete clinical response had a significantly higher proportion of women and lower proportion with diabetes, stroke or left ventricular hypertrophy. They also had a significantly shorter duration of hypertension, lower BMI, higher eGFR and lower defined daily dose of antihypertensives at baseline. In contrast, these differences were not observed in those with a complete, partial or absent biochemical response. The defined daily dose of targeted therapy did not differ across the various response categories. In conclusion, we have established an international expert consensus for standardized criteria to evaluate the response to targeted medical treatment of PA, facilitate comparisons of outcome data and guide clinicians who manage PA. In a retrospective international cohort, less than half of medically-treated patients reached the established biochemical treatment targets. Further work is needed to increase the rate of complete response. Presentation: 6/3/2024
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda
Ferguson, J , Solà, Elsa , Pérez, María Alejandra , Piano, Salvatore , Cheng, Alice G. , Subramanian, Aruna , Kim, W. Ray , Cheng, Alice , Subramanian, Aruna K , Piano, Salvatore , Toll, Jessica Ferguson , Perez, Maria Alejandra

Hepatology Communications | October 4, 2024 | Volume: 8 | Issue: 10 | Pages: No page available

10.1097/hc9.0000000000000539 | PMID 39365139 Get It

Bacterial infections in patients with cirrhosis lead to a 4-fold increase in mortality. Immune dysfunction in cirrhosis further increases the risk of bacterial infections, in addition to alterations in the gut microbiome, which increase the risk of pathogenic bacteria. High rates of empiric antibiotic use contribute to increased incidence of multidrug-resistant organisms and further increases in mortality. Despite continous advances in the field, major unknowns regarding interactions between the immune system and the gut microbiome and strategies to reduce infection risk and improve mortality deserve further investigation. Here, we highlight the unknowns in these major research areas and make a proposal for a research agenda to move toward improving disease progression and outcomes in patients with cirrhosis and infections.
eQTL in diseased colon tissue identifies novel target genes associated with IBD
Furey, Terrence S. , Nishiyama, Nina C. , Silverstein, Sophie , Darlington, Kimberly , Ng, Meaghan Kennedy, Clough, Katelyn , Bauer, Mikaela J., Beasley, Caroline, Bharadwaj, Akshatha, Ganesan, Rajee , Lau, Gwen, Lian, Grace , Rahbar, Reza, Sadiq, Timothy S., Schaner, Matthew R. , Stem, Jonathan, Friton, Jessica, Faubion, William A. , Sheikh, Shehzad Z. , Ng, Meaghan M. Kennedy , Kapadia, Muneera Rehana

No container title available | October 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5147457/v1 Get It

Abstract Genome-wide association studies (GWAS) have identified over 300 loci associated with the inflammatory bowel diseases (IBD), but putative causal genes for most are unknown. We conducted the largest disease-focused expression quantitative trait loci (eQTL) analysis using colon tissue from 252 IBD patients to determine genetic effects on gene expression and potential contribution to IBD. Combined with two non-IBD colon eQTL studies, we identified 194 potential target genes for 108 GWAS loci. eQTL in IBD tissue were enriched for IBD GWAS loci colocalizations, provided novel evidence for IBD-associated genes such as ABO and TNFRSF14, and identified additional target genes compared to non-IBD tissue eQTL. IBD-associated eQTL unique to diseased tissue had distinct regulatory and functional characteristics with increased effect sizes. Together, these highlight the importance of eQTL studies in diseased tissue for understanding functional consequences of genetic variants, and elucidating molecular mechanisms and regulation of key genes involved in IBD.
Assessment and impact of age on the efficacy and safety among patients in the etrasimod ELEVATE UC clinvical programme
Lichtenstein, Gary, Allegretti, Jessica R. , Irving, Peter M., Charabaty, Aline, Kuehbacher, Tanja, Bananis, Eustratios , Woolcott, John , Dalam, Alexis B, Lazin, K., Keating, Michael J. , McDonnell, A, Allegretti, Jessica R. , Loftus, Edward V. , Banerjee, Rupa , Charabaty, Aline , Lazin, Krisztina , Danese, Silvio

Zeitschrift für Gastroenterologie | October 2, 2024 | Volume: 62 | Issue: 09 | Pages: e605-e606

10.1055/s-0044-1789701 Get It

How to build and operationalise a hospital command centre
Crawley, Danielle, Engler, Nicole, Stellmaker, Jessica, Buechler, Tamara, Bany, Mary, Dangerfield, Benjamin, Newman, James S. , Stellmaker, Jessica A.

Management in Healthcare: A Peer-Reviewed Journal | October 1, 2024 | Volume: 9 | Issue: 1 | Pages: 46

10.69554/eftp6260 Get It

In the ever-evolving healthcare landscape, hospitals routinely grapple with daily disruptions and unforeseen events affecting resources and capacity. This paper explores the implementation and impact of the Rochester Hospital Operations Command Center (RHOCC) as a strategic response to challenges faced by the Mayo Clinic Hospital campuses in Rochester. The RHOCC, developed with an expedited timeline in response to capacity issues, exacerbated by COVID-19, serves as a centralised hub for real-time monitoring, coordination and decision-making related to patient flow. The process of establishing the command centre involved role identification, skill set determination, location of important personnel in an organised central space and vendor selection to develop the necessary infrastructure. Dashboards were developed to provide real-time actionable insights into external transfers, surgical and other planned admissions, emergency department status, patient throughput and discharges. These dashboards include colour-coded keys highlighting thresholds related to patient flow metrics and are used to facilitate daily huddles and enhance transparency and data-driven decision-making among hospital stakeholders. The outcomes of implementing the RHOCC include improved efficiency and collaboration, as well as a significantly enhanced ability to proactively respond to factors affecting census. The development of a command centre — driven by leadership endorsement and a commitment to continuous improvement — emerges as a transformative strategy in healthcare innovation. The RHOCC’s approach of building capability, fostering inclusion and articulating a vision of providing superior care while driving impactful improvements, positions it as a leading force in creating operational efficiencies to define healthcare delivery.